“Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis”, J of Skin, vol. 7, no. 6, p. s251, Nov. 2023, doi: 10.25251/skin.7.supp.251.